Adults living with a slow-progressing kidney disease that often shows no symptoms until organ function collapses now have a new treatment option. On November 25, 2025, the FDA cleared VOYXACT (sibeprenlimab-szsi) for adults with primary immunoglobulin A nephropathy, or IgAN, who face a risk of disease progression. The decision, granted under accelerated approval, makes VOYXACT the first biologic designed to block APRIL, a protein central to the immune attack that damages kidneys in IgAN. For patients who may not realize their kidneys are failing until protein spills into their urine and filtration rates drop, the approval opens a targeted path that did not exist even a few years ago. Details of the decision are outlined in the FDA’s announcement of a new treatment for primary IgA nephropathy.
Why blocking APRIL changes the calculus for IgAN patients
IgAN is the most common form of primary glomerulonephritis worldwide, yet it can smolder for years without clear warning signs. Abnormal immunoglobulin A deposits accumulate in the kidney’s filtering units, triggering inflammation and scarring. By the time many patients learn their diagnosis, they already show elevated protein in their urine, a marker tied to long-term kidney decline. Standard care has relied on blood-pressure drugs called RAS inhibitors and, since 2021, a single disease-specific medication: Tarpeyo, a targeted-release budesonide that became the first drug the FDA approved to decrease urine protein in IgAN, as described in the agency’s notice on the first drug for this rare kidney disease.
VOYXACT works through a different mechanism. Rather than dampening inflammation broadly, sibeprenlimab targets APRIL, a cytokine that fuels the production of the defective IgA1 antibodies responsible for kidney damage. The hypothesis driving its development is direct: if clinicians can cut off the immune signal earlier in the disease chain, they may slow or halt the silent march toward kidney failure and dialysis. Whether that hypothesis holds over five or more years is the central question the field now needs to answer. Specifically, early use of APRIL inhibition should produce a measurable reduction in progression to advanced chronic kidney disease compared with regimens focused only on lowering proteinuria, a claim that registry data and ongoing trial follow-up can test.
VISIONARY trial data and the accelerated approval pathway
The FDA based its decision on interim results from the Phase 3 VISIONARY trial, a randomized study of sibeprenlimab in IgAN patients. Investigators reported that VOYXACT reduced proteinuria, measured by the urine protein-to-creatinine ratio (UPCR), compared with placebo on top of standard background therapy. These findings are summarized in a New England Journal article describing the VISIONARY trial’s design and primary results. According to the FDA, the endpoint supporting accelerated approval was the magnitude and durability of UPCR reduction over the trial period. That surrogate marker is considered reasonably likely to predict clinical benefit, but it is not the same as demonstrating preserved kidney function or avoidance of dialysis over the long term.
Accelerated approval carries a specific obligation. The manufacturer, Otsuka, must complete confirmatory studies showing that the proteinuria reduction translates into durable kidney protection. The FDA’s Drug Trials Snapshots for VOYXACT document the demographics of enrolled participants, including breakdowns by sex, race, and age, providing transparency about whose outcomes shaped the approval. Trial registration records on ClinicalTrials.gov detail the study design, including dosing schedules, background RAS inhibition, and follow-up plans for kidney function and safety outcomes. Together, these sources sketch a picture of a therapy that has cleared an important regulatory bar but still sits at an interim point on the evidence curve.
The earlier IgAN-specific approval, Tarpeyo, followed a similar accelerated path. Its supporting evidence came from the NefIgArd trial, a randomized Phase 3 study of targeted-release budesonide whose two-year results were published in peer-reviewed journals and showed effects on both UPCR and estimated glomerular filtration rate (eGFR). Both drugs earned their initial clearance on proteinuria endpoints, which creates a tension: the FDA accepted UPCR as the basis for approving VOYXACT, while Tarpeyo already holds the distinction of being the first drug cleared to decrease urine protein in IgAN. What separates VOYXACT is its mechanism, not the surrogate it was measured against. Clinically, that distinction matters because APRIL inhibition acts upstream in the disease pathway, while gut-targeted steroids modulate mucosal immunity more broadly.
Gaps in long-term evidence and what patients should watch
The most consequential unknown is whether APRIL inhibition will preserve kidney function better than existing options over years, not months. The VISIONARY interim analysis provides a snapshot of proteinuria changes, but long-term eGFR slope data, the measure that tracks how fast kidneys lose filtering capacity, have not yet appeared in primary FDA review documents. No head-to-head trial has compared VOYXACT against Tarpeyo on hard clinical endpoints such as time to dialysis, kidney transplant, or a sustained 40 percent decline in eGFR. Without that comparison, clinicians and patients are left to weigh two accelerated-approval drugs that share a surrogate endpoint but attack the disease through very different biological pathways.
Post-marketing safety is another open file. Real-world adherence patterns and adverse-event signals beyond the controlled environment of a clinical trial can shift the risk-benefit balance in subtle ways. VOYXACT’s mechanism raises particular questions about infection risk and immune modulation, especially in patients who may also be taking other immunosuppressive medications. The FDA’s prescribing information outlines observed side effects during the trial period, but rarer events or complications that emerge only with longer exposure will require careful pharmacovigilance and registry follow-up.
For patients, the practical questions cluster around eligibility, monitoring, and expectations. VOYXACT is indicated for adults with primary IgAN who are at risk of disease progression, a category that typically includes people with persistent proteinuria despite optimized RAS blockade. That means nephrologists will need to confirm the diagnosis, quantify UPCR over time, and assess eGFR trends before recommending therapy. Once on treatment, regular lab checks for kidney function, proteinuria, and potential side effects will be essential to gauge whether the drug is delivering meaningful benefit.
Shared decision-making will also have to grapple with uncertainty. Some patients may prioritize a mechanism that targets the root of the abnormal IgA response, even if long-term data are incomplete. Others may prefer to start with therapies that have more mature eGFR data, such as Tarpeyo, or to remain on optimized supportive care until confirmatory VOYXACT results are available. Cost, insurance coverage, and logistical factors like infusion schedules or clinic visits could further tilt decisions in one direction or another.
For clinicians, VOYXACT’s arrival signals a broader shift in IgAN management from non-specific supportive care toward mechanism-based combinations. In practice, that could mean layering APRIL inhibition on top of RAS blockers, SGLT2 inhibitors, and, when appropriate, gut-targeted steroids, with each component aimed at a different node in the disease network. As more data emerge, nephrologists will likely refine which patients benefit most from early APRIL blockade-those with high-risk genetic markers, rapidly rising proteinuria, or particular patterns of biopsy findings-and which can be managed with less intensive regimens.
The approval also underscores how much hinges on surrogate endpoints in rare and slowly progressive diseases. By accepting proteinuria reduction as “reasonably likely” to predict benefit, the FDA has enabled earlier access to a promising therapy while explicitly tying that access to the completion of long-term outcome trials. For the IgAN community, the next several years will determine whether VOYXACT’s early promise translates into fewer dialysis starts, fewer transplants, and a slower erosion of kidney function. Until those answers arrive, patients and providers will need to balance optimism about a new biologic option with caution about what remains unknown.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
